Takeda Pharmaceutical Company Limited TAK
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 9.78% | -9.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.78% | -9.80% | |||
| Cost of Revenue | -11.64% | 10.99% | |||
| Gross Profit | 24.92% | -20.34% | |||
| SG&A Expenses | -3.34% | 1.40% | |||
| Depreciation & Amortization | -0.05% | -24.99% | |||
| Other Operating Expenses | 181.48% | -194.03% | |||
| Total Operating Expenses | 3.18% | -10.06% | |||
| Operating Income | 62.56% | -7.64% | |||
| Income Before Tax | 135.22% | -433.83% | |||
| Income Tax Expenses | 156.25% | -382.32% | |||
| Earnings from Continuing Operations | 130.28% | -448.79% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 4.68% | 35.22% | |||
| Net Income | 130.26% | -449.17% | |||
| EBIT | 62.56% | -7.64% | |||
| EBITDA | 85.85% | -40.83% | |||
| EPS Basic | 130.26% | -448.85% | |||
| Normalized Basic EPS | 123.22% | -38.55% | |||
| EPS Diluted | 129.80% | -454.76% | |||
| Normalized Diluted EPS | 119.78% | -37.52% | |||
| Average Basic Shares Outstanding | 0.00% | 0.08% | |||
| Average Diluted Shares Outstanding | 1.56% | -1.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | 56.62% | -1.02% | |||